ArticleFrontiers in oncology2020
Prognostication of Half-Life Clearance of Plasma EBV DNA in Previously Untreated Non-metastatic Nasopharyngeal Carcinoma Treated With Radical Intensity-Modulated Radiation Therapy.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06480903 (Exploratory Study of Plasma Epstein Barr Virus), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exploratory Study of Plasma Epstein Barr Virus (EBV) DNA Clearance During Proton Beam Therapy (PBT) for Nasopharyngeal Carcinoma (NPC)
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Most Efficacious Induction Chemotherapy Regimen for Locoregionally Advanced Nasopharyngeal Carcinoma: A Network Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Circulating cell-free Epstein-Barr virus DNA measurement for nasopharyngeal carcinoma: advancing towards ctDNA-guided, risk-adaptive individualized treatment.Science China. Life sciences · 2026Review
- Epstein-Barr virus based biomarkers and targeted therapies in nasopharyngeal carcinoma: a narrative review.The Lancet regional health. Western Pacific · 2026Review
- A time-adapted risk stratification framework guided by longitudinal post-radiotherapy EBV DNA clearance for high-risk nasopharyngeal carcinoma patients.Radiation oncology (London, England) · 2026Article
- MB based RT-qPCR increase the clinical application of cfEBV DNA for NPC in non-endemic area of China.Scientific reports · 2025Article
- Radiation therapy with phenotypic medicine: towards N-of-1 personalization.British journal of cancer · 2024Review
- The whole-blood Epstein-Barr virus DNA can serve as a valuable molecular marker for diagnosis and prognosis prediction of nasopharyngeal carcinoma.American journal of cancer research · 2023Article
- Review
- Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges.Science advances · 2022Review
- Epstein-Barr virus dynamics and its prognostic impact on nasopharyngeal cancers in a non-endemic region.Ecancermedicalscience · 2022Article
- CDKN2B-AS1 promotes the proliferation, clone formation, and invasion of nasopharyngeal carcinoma cells by regulating miR-98-5p/E2F2 axis.American journal of translational research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.